Protalix BioTherapeutics, Inc. (PLX) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Biotechnology
EV/EBITDA
↑
N/A
—
5yr avg: 19.70
30Y Low12.9·High37.9
P/FCF
N/A
—
5yr avg: 20.62
30Y Low20.6·High133.1
P/B Ratio
↓
3.22
↓-11% vs avg
5yr avg: 3.61
30Y Low1.2·High89.0
ROE
↓
-14.4%
↑-166% vs avg
5yr avg: 21.9%
30Y Low-421%·High73%
Debt/EBITDA
↓
N/A
—
5yr avg: 1.72
30Y Low1.1·High16.1
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PLX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Protalix BioTherapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $159M | $141M | $152M | $147M | $66M | $37M | $106M | $49M | $46M | $87M | $451M |
| Enterprise Value | $153M | $135M | $138M | $151M | $83M | $31M | $152M | $92M | $56M | $88M | $465M |
| P/E Ratio → | -23.54 | — | 51.37 | 17.80 | — | — | — | — | — | — | — |
| P/S Ratio | 3.02 | 2.68 | 2.85 | 2.24 | 1.39 | 0.96 | 1.68 | 0.89 | 1.34 | 4.11 | 49.05 |
| P/B Ratio | 3.22 | 2.93 | 3.53 | 4.37 | — | — | — | — | — | — | — |
| P/FCF | — | — | 20.62 | — | — | — | — | — | — | — | — |
| P/OCF | — | — | 17.57 | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PLX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.56 | 2.59 | 2.30 | 1.74 | 0.81 | 2.42 | 1.68 | 1.63 | 4.16 | 50.59 |
| EV / EBITDA | — | — | 26.46 | 12.94 | — | — | 37.87 | — | — | — | — |
| EV / EBIT | — | — | 26.49 | 12.84 | — | — | 48.27 | — | — | — | — |
| EV / FCF | — | — | 18.69 | — | — | — | — | — | — | — | — |
PLX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Protalix BioTherapeutics, Inc. earns an operating margin of -10.4%. Operating margins have compressed from 16.0% to -10.4% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -14.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 48.8% | 48.8% | 54.5% | 64.9% | 58.9% | 57.4% | 82.7% | 80.1% | 72.8% | 27.7% | 8.7% |
| Operating Margin | -10.4% | -10.4% | 7.3% | 16.0% | -27.3% | -53.4% | 4.3% | -19.6% | -56.4% | -163.8% | -360.5% |
| Net Profit Margin | -12.5% | -12.5% | 5.5% | 12.7% | -31.3% | -71.9% | -10.4% | -33.4% | -77.3% | -395.9% | -319.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -14.4% | -14.4% | 7.6% | 72.5% | — | — | — | — | — | — | -6411.6% |
| ROA | -8.5% | -8.5% | 3.7% | 11.9% | -23.1% | -39.0% | -11.5% | -34.3% | -39.7% | -108.0% | -32.7% |
| ROIC | -11.6% | -11.6% | 8.8% | 36.2% | -170.5% | -406.7% | — | — | — | — | -457.5% |
| ROCE | -10.6% | -10.6% | 9.0% | 33.6% | -40.8% | -186.5% | — | -52.3% | -45.3% | -105.4% | -65.0% |
PLX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $15M exceeds total debt of $8M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.17 | 0.17 | 0.13 | 0.82 | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | 1.06 | 2.38 | — | — | 16.05 | — | — | — | — |
| Net Debt / Equity | — | -0.13 | -0.33 | 0.12 | — | — | — | — | — | — | — |
| Net Debt / EBITDA | — | — | -2.73 | 0.35 | — | — | 11.50 | — | — | — | — |
| Debt / FCF | — | — | -1.93 | — | — | — | — | — | — | — | — |
| Interest Coverage | -4.62 | -4.62 | 3.69 | 3.29 | -5.15 | -2.72 | 0.28 | -1.35 | -2.51 | -3.55 | -7.91 |
Net cash position: cash ($15M) exceeds total debt ($8M)
PLX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Protalix BioTherapeutics, Inc.'s current ratio of 2.51x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 1.54x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 1.54x to 2.51x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.51 | 2.51 | 2.34 | 1.54 | 1.38 | 1.86 | 0.64 | 0.81 | 2.09 | 2.75 | 1.09 |
| Quick Ratio | 1.54 | 1.54 | 1.52 | 1.12 | 0.87 | 1.32 | 0.49 | 0.61 | 1.75 | 2.41 | 1.01 |
| Cash Ratio | 1.14 | 1.14 | 1.36 | 0.98 | 0.68 | 1.18 | 0.45 | 0.44 | 1.49 | 2.25 | 0.96 |
| Asset Turnover | — | 0.64 | 0.73 | 0.78 | 0.85 | 0.52 | 0.93 | 1.20 | 0.56 | 0.29 | 0.11 |
| Inventory Turnover | 1.05 | 1.05 | 1.14 | 1.21 | 1.17 | 0.91 | 0.83 | 1.34 | 1.09 | 1.94 | 1.60 |
| Days Sales Outstanding | — | 61.17 | 19.88 | 29.38 | 35.14 | 32.76 | 11.61 | 31.37 | 50.41 | 29.80 | 27.50 |
PLX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Protalix BioTherapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 1.9% | 5.6% | — | — | — | — | — | — | — |
| FCF Yield | — | — | 4.9% | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $79M | $81M | $82M | $48M | $44M | $29M | $15M | $15M | $13M | $101M |
Peer Comparison
Compare PLX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PLXYou | $159M | -23.5 | — | — | 48.8% | -10.4% | -14.4% | -11.6% | — |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 SRPT | $2B | -2.9 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 PTCT | $5B | 8.3 | 5.4 | 7.6 | 95.9% | 49.5% | — | — | 0.5 |
 BMRN | $10B | 30.1 | 15.9 | 14.4 | 77.1% | 16.6% | 5.9% | 7.4% | 1.0 |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 IONS | $13B | -31.9 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 LGND | $4B | -956.0 | 322.1 | 53.4 | 93.4% | -13.5% | -0.5% | -2.3% | 0.6 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See PLX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PLX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PLX vs RARE
Side-by-side business, growth, and profitability comparison vs Ultragenyx Pharmaceutical Inc..
Start ComparisonPLX — Frequently Asked Questions
Quick answers to the most common questions about buying PLX stock.
What is Protalix BioTherapeutics, Inc.'s P/E ratio?
Protalix BioTherapeutics, Inc.'s current P/E ratio is -23.5x. The historical average is 28.6x.
What is Protalix BioTherapeutics, Inc.'s ROE?
Protalix BioTherapeutics, Inc.'s return on equity (ROE) is -14.4%. The historical average is -55.3%.
Is PLX stock overvalued?
Based on historical data, Protalix BioTherapeutics, Inc. is trading at a P/E of -23.5x. Compare with industry peers and growth rates for a complete picture.
What are Protalix BioTherapeutics, Inc.'s profit margins?
Protalix BioTherapeutics, Inc. has 48.8% gross margin and -10.4% operating margin.